Biscayne Pharmaceuticals

About:

Biscayne Pharmaceuticals discovers and develops novel therapies based on growth hormone-releasing hormone (GHRH) analogs.

Website: http://biscaynepharma.com

Top Investors: Quark Venture, Mesa Verde Venture Partners, Florida Institute for the Commercialization of Florida Technology, GF Securities, The Reich Group

Description:

Biscayne Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops therapies based on growth hormone-releasing hormone (GHRH) analogs. The compounds include GHRH antagonists in development for the treatment of cancer, including castrate-resistant prostate cancer, and GHRH agonists for the repair of cardiac damage in heart disease patients. The company was incorporated in 2012 and is headquartered in Miami, Florida.

Total Funding Amount:

$11.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Miami, Florida, United States

Founded Date:

2012-01-01

Founders:

Jared Mendel, Joshua Michael Hare, Samuel J. Reich

Number of Employees:

11-50

Last Funding Date:

2017-01-31

IPO Status:

Private

Industries:

© 2025 bioDAO.ai